Arkg Stock Forecast: Short Term and Long Term Fund Price Analysis

Let's take a closer look at the Arkg stock forecast, which has been gaining attention in recent times. The stock has shown significant growth, with a 5-year return of 234%.

The Arkg stock price has been steadily increasing, with a current price of around $140. This is a 10% increase from the previous quarter. The stock's growth can be attributed to its strong performance in the biotech sector.

Investors are looking for a long-term gain, and the Arkg stock forecast suggests a potential 20% increase in the next 5 years. However, this is a relatively conservative estimate, and the stock's actual performance may vary.

A different take: Arkg

The ARKG fund price may drop from 24.54 USD to 23.363 USD, a change of -4.794%. This prediction is based on historical trends and may not reflect future performance.

Historically, ARK Genomic Revolution ETF has risen by an average of 15.6% over the next 52 weeks, based on the past 10 years of stock performance.

If you're interested in buying ARK Genomic Revolution ETF stock online, you can do so by opening an account at a top-tier brokerage firm, such as TD Ameritrade or tastyworks.

The ARK Genomic Revolution ETF has a short-term forecast that's worth checking out. The fund's price is expected to fluctuate in the next few days, with a predicted high of $26.481 on March 4, 2025.

The forecast for the next days and weeks shows a steady increase in price, with a minimum price of $24.421 on March 3, 2025, and a maximum price of $26.900 on March 5, 2025.

The ARK Genomic Revolution ETF is a publicly traded company, which means you can buy shares online through top-tier brokerage firms like TD Ameritrade or tastyworks.

Here's a summary of the forecast for the next days and weeks:

The stock price is also expected to increase after major news, with a predicted price of $25.62 after the latest traded price of $24.54.

To accurately predict the fund price, let's take a closer look at the current options market. Implied volatility is currently at 48.53%, a 2.99% increase from the previous day.

The historical volatility is slightly lower at 47.62%. This suggests that the market is expecting some level of price movement, but not as extreme as the current implied volatility.

The IV percentile is at 85%, indicating that the current implied volatility is higher than 85% of historical data. This could be a sign of increased market uncertainty.

The IV rank is 49.62%, which is relatively high. This means that the fund's options are trading at a higher volatility level compared to other funds in the market.

The put-call volume ratio is 0.59, indicating that there are more calls being bought than puts. This could be a sign of market optimism.

The volume and open interest numbers are also worth noting. Today's volume is 13,196, while the 30-day average is 26,275. This suggests that the market is relatively active today.

Here's a summary of the key numbers:

The put-call open interest ratio is 0.60, similar to the put-call volume ratio. This suggests that the market is expecting more calls to be exercised than puts.

A fresh viewpoint: Compared to Growth Stocks Value Stocks' Price-earnings Ratio Is Typically

The ARK Genomic Revolution ETF has some interesting predictions. On average, it has historically risen by 15.6% over the next 52 weeks based on past 10 years of stock performance.

Looking at short-term predictions, the fund's price may drop from $24.540 USD to $23.363 USD, with a change of -4.794%. This prediction is based on a specific analysis.

In terms of price range, the fund's price is expected to fluctuate between $24.421 and $26.023 on March 3rd, and between $24.767 and $26.325 on March 11th.

The fund's price is also expected to rise to $25.62 after a major news event, with a potential return of 0.04.

In the ARKG stock forecast, the fund has consistently delivered strong returns, with a 5-year annualized return of 34.6%. This is largely due to its focus on biotechnology and genomics stocks.

The ARKG fund has a high turnover rate, with an average holding period of just 1.4 months. This indicates a highly active trading strategy.

Discover more: Arkg Holdings

The fund's top holdings include Editas Medicine, which has a market capitalization of over $1.5 billion. This is significant, as Editas Medicine is a leading player in the field of gene editing.

CRISPR Therapeutics is another top holding, with a market capitalization of over $4.5 billion. This company is developing innovative gene editing treatments for a range of diseases.

The ARKG fund has a significant allocation to smaller-cap biotech stocks, with over 50% of its portfolio invested in companies with market capitalizations under $1 billion. This is a key factor in the fund's high-risk, high-reward approach.

Readers also liked: Top 20 Altcoins

The ARKG stock has a market capitalization of around $12 billion, which is relatively small compared to other ETFs in the market.

One of the key factors driving the growth of ARKG stock is its focus on innovative companies in the biotech and pharmaceutical sectors.

The ARKG stock has a high beta of 2.1, indicating that it is a relatively high-risk investment.

Related reading: Why Are Bitcoins so High

The fund's management team, led by Catherine Wood, has a proven track record of identifying and investing in companies that are poised for significant growth.

The ARKG stock has a dividend yield of 0%, indicating that the fund does not distribute any dividends to its investors.

The fund's expense ratio is 0.75%, which is relatively low compared to other ETFs in the market.

Investors in ARKG stock are exposed to a range of risks, including regulatory risks, clinical trial risks, and competitive risks.

The ARKG stock has a 5-year annualized return of around 45%, which is significantly higher than the S&P 500's return over the same period.

Here's an interesting read: How Are Stock Speculators Different from Stock Investors

The ARK Genomic Revolution fund has experienced price drops in the past, with a possible decrease from $24.540 USD to $23.363 USD, representing a -4.794% change.

Historically, the ARK Genomic Revolution ETF has shown an average increase of 15.6% over the next 52 weeks, based on its past 10 years of stock performance.

It's worth noting that this 15.6% average increase is a historical trend, not a guaranteed prediction for the future.

The fund's price drop from $24.540 USD to $23.363 USD is a specific prediction, but it's unclear why the 2023 prediction is lower than expected, or if this is an error in the calculation or if the ETF is planned to be dissolved.

The ARKG stock forecast is a topic of interest for many investors. Historically, ARK Genomic Revolution ETF has risen by 15.6% on average over the next 52 weeks based on the past 10 years of stock performance.

The current share price of ARKG is $25.63, which is lower than its historic median score of 50, indicating higher risk than normal. ARKG is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.

According to historical data, ARK Genomic Revolution ETF has risen higher in 5 of the past 10 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%. This suggests that there is a chance for the stock to rise in the near future.

Here is a summary of the forecasted price range for ARKG over the next few days:

The ARK Genomic Revolution fund price may drop from $24.540 USD to $23.363 USD, resulting in a -4.794% change. This potential drop is based on a prediction.

Historically, the fund has seen significant fluctuations in its price. Over the past 10 years, the fund has on average risen by 15.6% over the next 52 weeks.

However, this time around, the prediction suggests a drop, not a rise. It's unclear why the 2023 prediction is down, but it's possible that this is an error in the calculation.

If you're considering investing in the ARK Genomic Revolution fund, it's essential to keep an eye on its performance and adjust your strategy accordingly.

Over the next 52 weeks, ARK Genomic Revolution ETF has on average historically risen by 15.6% based on the past 10 years of stock performance.

Historically, the stock has risen higher in 5 of those 10 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%. This suggests that there's a reasonable chance the price could go up, but it's not a guarantee.

The current ARK Genomic Revolution ETF [ARKG] share price is $25.63. The Score for ARKG is 30, which is 40% below its historic median score of 50, and infers higher risk than normal.

However, the Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction. This suggests that the technical analysis is positive, but it's essential to consider other factors as well.

Based on the historical data, it's worth noting that the stock has been in a strongly bearish trend, with the share price being below its 5, 20 & 50 day exponential moving averages.